BR112022019038A2 - Ofatumumab para tratamento de em enquanto mantém a igg sérica - Google Patents
Ofatumumab para tratamento de em enquanto mantém a igg séricaInfo
- Publication number
- BR112022019038A2 BR112022019038A2 BR112022019038A BR112022019038A BR112022019038A2 BR 112022019038 A2 BR112022019038 A2 BR 112022019038A2 BR 112022019038 A BR112022019038 A BR 112022019038A BR 112022019038 A BR112022019038 A BR 112022019038A BR 112022019038 A2 BR112022019038 A2 BR 112022019038A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- serum igg
- ofatumumab
- cell
- level
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169007 | 2020-04-09 | ||
| EP20176057 | 2020-05-22 | ||
| US202063076628P | 2020-09-10 | 2020-09-10 | |
| US202163166054P | 2021-03-25 | 2021-03-25 | |
| PCT/EP2021/059285 WO2021204994A1 (en) | 2020-04-09 | 2021-04-09 | Ofatumumab for treating ms while maintaining serum igg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019038A2 true BR112022019038A2 (pt) | 2022-11-01 |
Family
ID=75362645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019038A BR112022019038A2 (pt) | 2020-04-09 | 2021-04-09 | Ofatumumab para tratamento de em enquanto mantém a igg sérica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230151106A1 (https=) |
| EP (3) | EP4707302A2 (https=) |
| JP (2) | JP7794757B2 (https=) |
| KR (1) | KR20220166827A (https=) |
| CN (1) | CN115427068A (https=) |
| AU (1) | AU2021253674A1 (https=) |
| BR (1) | BR112022019038A2 (https=) |
| CA (1) | CA3176574A1 (https=) |
| DE (1) | DE202021004005U1 (https=) |
| IL (1) | IL296701A (https=) |
| MX (1) | MX2022012600A (https=) |
| WO (1) | WO2021204994A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| WO2012018704A1 (en) * | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2748198A2 (en) * | 2011-09-27 | 2014-07-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| LT3733712T (lt) * | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| MX2022003010A (es) * | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) * | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2021
- 2021-04-09 EP EP25215090.9A patent/EP4707302A2/en active Pending
- 2021-04-09 MX MX2022012600A patent/MX2022012600A/es unknown
- 2021-04-09 DE DE202021004005.6U patent/DE202021004005U1/de active Active
- 2021-04-09 AU AU2021253674A patent/AU2021253674A1/en active Pending
- 2021-04-09 WO PCT/EP2021/059285 patent/WO2021204994A1/en not_active Ceased
- 2021-04-09 JP JP2022561400A patent/JP7794757B2/ja active Active
- 2021-04-09 CN CN202180027438.7A patent/CN115427068A/zh active Pending
- 2021-04-09 US US17/995,820 patent/US20230151106A1/en active Pending
- 2021-04-09 EP EP21716231.2A patent/EP4132564A1/en active Pending
- 2021-04-09 BR BR112022019038A patent/BR112022019038A2/pt not_active Application Discontinuation
- 2021-04-09 IL IL296701A patent/IL296701A/en unknown
- 2021-04-09 CA CA3176574A patent/CA3176574A1/en active Pending
- 2021-04-09 EP EP25220406.0A patent/EP4682171A3/en active Pending
- 2021-04-09 KR KR1020227038773A patent/KR20220166827A/ko active Pending
-
2025
- 2025-09-11 JP JP2025151221A patent/JP2026009900A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023521754A (ja) | 2023-05-25 |
| EP4682171A2 (en) | 2026-01-21 |
| DE202021004005U1 (de) | 2022-05-06 |
| EP4682171A3 (en) | 2026-05-06 |
| CA3176574A1 (en) | 2021-10-14 |
| US20230151106A1 (en) | 2023-05-18 |
| WO2021204994A1 (en) | 2021-10-14 |
| EP4132564A1 (en) | 2023-02-15 |
| JP7794757B2 (ja) | 2026-01-06 |
| MX2022012600A (es) | 2023-02-15 |
| EP4707302A2 (en) | 2026-03-11 |
| KR20220166827A (ko) | 2022-12-19 |
| IL296701A (en) | 2022-11-01 |
| JP2026009900A (ja) | 2026-01-21 |
| CN115427068A (zh) | 2022-12-02 |
| AU2021253674A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019038A2 (pt) | Ofatumumab para tratamento de em enquanto mantém a igg sérica | |
| BR112021022789A2 (pt) | Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| Vowden et al. | The effect of amelogenins (Xelma™) on hard‐to‐heal venous leg ulcers | |
| Lighthouse et al. | Exercise promotes a cardioprotective gene program in resident cardiac fibroblasts | |
| Watanabe et al. | PERIOSTIN regulates MMP-2 expression via the αvβ3 integrin/ERK pathway in human periodontal ligament cells | |
| Yanaba et al. | Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| ATE411018T1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
| NO20040731L (no) | Medisinsk bruk av histon-deacetylase inhibitor og fremgangsmate og evaluering av dens antitumor-virkning. | |
| MX2021003845A (es) | Composiciones para reducir el acido urico serico. | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| BR112022001341A2 (pt) | Inibidores de enzima | |
| MX2022014931A (es) | Métodos de evaluacion del riesgo de desarrollar una respuesta severa a la infección por coronavirus. | |
| BR112019009495A2 (pt) | métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes | |
| CY1126058T1 (el) | Αγωγη μιτοχονδριακων παθησεων | |
| BR112022004851A2 (pt) | Uso de inibidores de dkk-1 para tratar câncer | |
| WO2022184942A3 (en) | Biomarkers | |
| BR0012408A (pt) | Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| Agyingi et al. | The Effect of Bacteria on Epidermal WoundHealing | |
| BR112022001138A2 (pt) | Métodos de tratamento de esclerose múltipla | |
| Müller et al. | Depression, emotional blunting, and akinesia in schizophrenia: overlap and differentiation | |
| EP1804789A4 (en) | METHOD FOR TREATING PREECLAMPSY IN HUMANS WITH RESIBUFAGENIN | |
| ATE422896T1 (de) | Eg-vegf/prokineticin 2 rezeptor antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024017958-0 PROTOCOLO 870240074712 EM 30/08/2024 16:12. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |